VALN News and Press, Valneva SE From 12/16/21

Pressure on tech stocks led to broad losses on Wall Street Thursday, with the Nasdaq falling about 2.5%. The prospect of higher interest rates, signaled by the Federal Reserve's recent hawkish turn, pointed to lower tech valuations on the way. However, elsewhere in the market, a rising rate e...

Valneva (NASDAQ:VALN) announces positive homologous booster data from the Phase 1/2 study, of its COVID-19 vaccine candidate, VLA2001. Initial results show excellent immune response after third dose of VLA2001 administered 7 to 8 months after the second dose of primary vaccination. Antibody t...

Valneva (NASDAQ:VALN) has signed an advance purchase agreement with the Kingdom of Bahrain for the supply of 1M doses of the its inactivated COVID-19 vaccine candidate VLA2001. Shares up 11.3% premarket at $53.40. This is the second purchase agreement VALN has secured for VLA2001 si...

Valneva SE (VALN -15.0%) blamed the design of a booster trial in the U.K. after its peer-reviewed data indicated that the company’s experimental COVID-19 vaccine underperformed rivals when given as a booster to those who received Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) vaccine in...

Gainers: Celyad Oncology CYAD +41%, Longeveron LGVN +28%, Petros Pharmaceuticals (NASDAQ:PTPI) +26%, AirSculpt Technologies AIRS +12%, Werewolf Therapeutics (NASDAQ:HOWL) +12%. Losers: Esperion Therapeutics ESPR -40%, Biofrontera (NASDAQ:...

According to a peer-reviewed study published in The Lancet on Thursday, Moderna (NASDAQ:MRNA) COVID-19 vaccine has shown the strongest antibody effect in a trial that evaluated the different combinations of COVID-19 vaccines as boosters. The Phase 2 "COV-Boost" study conducted acros...

Valneva SE (VALN -0.2%) announced that the company will test its experimental COVID-19 vaccine, VLA2001, against the newly found Omicron variant of coronavirus. However, it also noted that, as opposed to the vaccines that target only the spike protein of the virus, its whole-virus inactivated...

The European Union's (EU) drug regulator has started a rolling review of a new coronavirus vaccine made by French startup Valneva (NASDAQ:VALN). VALN shares up 2.5% premarket at $64.50. The review decision was based on preliminary studies that suggest the vaccine, VLA2001,...

Should Investors Be Watching These Top Biotech Stocks Right Now? Biotech stocks are among the most active stocks in the stock market today. Namely, a key factor contributing to this now would be the latest update on the Covid pandemic. Over the Thanksgiving weekend, global h...

Valneva SE (VALN +8.2%) ADRs are trading sharply higher for the second straight session on the announcement of a partnership with IDT Biologika to produce the company’s inactivated COVID-19 vaccine candidate VLA2001. Per the terms of the deal, IDT Biologika is expected to manufacture t...